E. Ohman J or Asset Management AB Boosts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

E. Ohman J or Asset Management AB lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,150 shares of the medical equipment provider’s stock after buying an additional 1,250 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Zimmer Biomet were worth $1,072,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Equity Investment Corp acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC raised its position in Zimmer Biomet by 49.1% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after purchasing an additional 577,320 shares in the last quarter. Van ECK Associates Corp raised its position in Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after purchasing an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at about $41,588,000. Finally, FMR LLC raised its position in Zimmer Biomet by 27.6% in the 3rd quarter. FMR LLC now owns 750,336 shares of the medical equipment provider’s stock valued at $80,999,000 after purchasing an additional 162,384 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZBH shares. Raymond James reduced their price target on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Barclays cut their target price on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research report on Thursday, December 12th. Truist Financial raised their target price on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, January 29th. Finally, Oppenheimer cut their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $124.11.

Zimmer Biomet Stock Up 0.4 %

Zimmer Biomet stock opened at $108.27 on Thursday. The stock’s 50 day moving average price is $107.82 and its 200 day moving average price is $108.20. The company has a market cap of $21.55 billion, a PE ratio of 20.58, a price-to-earnings-growth ratio of 1.88 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.